Integrated seroprevalence-based assessment of Wuchereria bancrofti and Onchocerca volvulus in two lymphatic filariasis evaluation units of Mali with the SD Bioline Onchocerciasis/LF IgG4 Rapid Test.


Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
01 2019
Historique:
received: 27 09 2018
accepted: 08 12 2018
revised: 11 02 2019
pubmed: 31 1 2019
medline: 24 4 2019
entrez: 31 1 2019
Statut: epublish

Résumé

Mali has become increasingly interested in the evaluation of transmission of both Wuchereria bancrofti and Onchocerca volvulus as prevalences of both infections move toward their respective elimination targets. The SD Bioline Onchocerciasis/LF IgG4 Rapid Test was used in 2 evaluation units (EU) to assess its performance as an integrated surveillance tool for elimination of lymphatic filariasis (LF) and onchocerciasis. A cross sectional survey with SD Bioline Onchocerciasis/LF IgG4 Rapid Test was piggy-backed onto a transmission assessment survey (TAS) (using the immunochromatographic card test (ICT) Binax Filariasis Now test for filarial adult circulating antigen (CFA) detection) for LF in Mali among 6-7 year old children in 2016 as part of the TAS in two EUs namely Kadiolo-Kolondieba in the region of Sikasso and Bafoulabe -Kita-Oussoubidiagna-Yelimane in the region of Kayes. In the EU of Kadiolo- Kolondieba, of the 1,625 children tested, the overall prevalence of W. bancrofti CFA was 0.62% (10/1,625) [CI = 0.31-1.09]; while that of IgG4 to Wb123 was 0.19% (3/1,600) [CI = 0.04-0.50]. The number of positives tested with the two tests were statistically comparable (p = 0.09). In the EU of Bafoulabe-Kita-Oussoubidiagna-Yelimane, an overall prevalence of W. bancrofti CFA was 0% (0/1,700) and that of Wb123 IgG4 antibody was 0.06% (1/1,700), with no statistically significant difference between the two rates (p = 0.99). In the EU of Kadiolo- Kolondieba, the prevalence of Ov16-specific IgG4 was 0.19% (3/1,600) [CI = 0.04-0.50]. All 3 positives were in the previously O. volvulus-hyperendemic district of Kolondieba. In the EU of Bafoulabe-Kita-Oussoubidiagna-Yelimane, an overall prevalence of Ov16-specific IgG4 was 0.18% (3/1,700) [CI = 0.04-0.47]. These 3 Ov16 IgG4 positives were from previously O.volvulus-mesoendemic district of Kita. The SD Bioline Onchocerciasis/LF IgG4 Rapid test appears to be a good tool for integrated exposure measures of LF and onchocerciasis in co-endemic areas.

Sections du résumé

BACKGROUND
Mali has become increasingly interested in the evaluation of transmission of both Wuchereria bancrofti and Onchocerca volvulus as prevalences of both infections move toward their respective elimination targets. The SD Bioline Onchocerciasis/LF IgG4 Rapid Test was used in 2 evaluation units (EU) to assess its performance as an integrated surveillance tool for elimination of lymphatic filariasis (LF) and onchocerciasis.
METHODOLOGY/PRINCIPAL FINDINGS
A cross sectional survey with SD Bioline Onchocerciasis/LF IgG4 Rapid Test was piggy-backed onto a transmission assessment survey (TAS) (using the immunochromatographic card test (ICT) Binax Filariasis Now test for filarial adult circulating antigen (CFA) detection) for LF in Mali among 6-7 year old children in 2016 as part of the TAS in two EUs namely Kadiolo-Kolondieba in the region of Sikasso and Bafoulabe -Kita-Oussoubidiagna-Yelimane in the region of Kayes. In the EU of Kadiolo- Kolondieba, of the 1,625 children tested, the overall prevalence of W. bancrofti CFA was 0.62% (10/1,625) [CI = 0.31-1.09]; while that of IgG4 to Wb123 was 0.19% (3/1,600) [CI = 0.04-0.50]. The number of positives tested with the two tests were statistically comparable (p = 0.09). In the EU of Bafoulabe-Kita-Oussoubidiagna-Yelimane, an overall prevalence of W. bancrofti CFA was 0% (0/1,700) and that of Wb123 IgG4 antibody was 0.06% (1/1,700), with no statistically significant difference between the two rates (p = 0.99). In the EU of Kadiolo- Kolondieba, the prevalence of Ov16-specific IgG4 was 0.19% (3/1,600) [CI = 0.04-0.50]. All 3 positives were in the previously O. volvulus-hyperendemic district of Kolondieba. In the EU of Bafoulabe-Kita-Oussoubidiagna-Yelimane, an overall prevalence of Ov16-specific IgG4 was 0.18% (3/1,700) [CI = 0.04-0.47]. These 3 Ov16 IgG4 positives were from previously O.volvulus-mesoendemic district of Kita.
CONCLUSIONS/SIGNIFICANCE
The SD Bioline Onchocerciasis/LF IgG4 Rapid test appears to be a good tool for integrated exposure measures of LF and onchocerciasis in co-endemic areas.

Identifiants

pubmed: 30699120
doi: 10.1371/journal.pntd.0007064
pii: PNTD-D-18-01466
pmc: PMC6370230
doi:

Substances chimiques

Antibodies, Helminth 0
Immunoglobulin G 0

Types de publication

Evaluation Study Journal Article Research Support, N.I.H., Intramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0007064

Subventions

Organisme : Intramural NIH HHS
ID : Z01 AI001063
Pays : United States
Organisme : NIAID NIH HHS
ID : Z01 AI001063
Pays : United States

Déclaration de conflit d'intérêts

I have read the journal's policy and the authors of this manuscript have the following competing interests: Thomas B. Nutman is among the patent holders for Wb123 and Ov16 (no longer under patent) and, through the National Institutes of Health, has received licensing/royalty fees for Wb123.

Références

Ann Trop Med Parasitol. 2002 Mar;96 Suppl 1:S29-39
pubmed: 12081248
J Infect Dis. 2006 Jul 15;194(2):216-21
pubmed: 16779728
Mali Med. 2006;21(1):12-7
pubmed: 17390523
Ann Trop Med Parasitol. 2008 Sep;102 Suppl 1:13-7
pubmed: 18718148
PLoS Negl Trop Dis. 2009 Jul 21;3(7):e497
pubmed: 19621091
Am J Trop Med Hyg. 2010 Jul;83(1):21-7
pubmed: 20595472
PLoS Negl Trop Dis. 2012;6(3):e1574
pubmed: 22448294
PLoS Negl Trop Dis. 2012;6(9):e1825
pubmed: 23029586
PLoS Negl Trop Dis. 2012;6(12):e1941
pubmed: 23236534
Am J Trop Med Hyg. 2013 Jul;89(1):11-5
pubmed: 23690552
Bull Soc Pathol Exot. 2015 Aug;108(3):181-7
pubmed: 25476256
Clin Vaccine Immunol. 2015 Aug;22(8):896-901
pubmed: 26018537
Parasit Vectors. 2016 Jun 13;9(1):338
pubmed: 27296630
Am J Trop Med Hyg. 2016 Dec 7;95(6):1417-1423
pubmed: 27729568
Parasit Vectors. 2016 Dec 3;9(1):628
pubmed: 27912789
PLoS Negl Trop Dis. 2017 Jan 23;11(1):e0005314
pubmed: 28114304
Epidemics. 2017 Mar;18:4-15
pubmed: 28279455
N Engl J Med. 2017 Nov 23;377(21):2044-2052
pubmed: 29116890
Am J Trop Med Hyg. 2018 Jan;98(1):15-20
pubmed: 29165213
Int Health. 2018 Mar 1;10(suppl_1):i14-i19
pubmed: 29471341
PLoS Negl Trop Dis. 2018 Mar 15;12(3):e0006249
pubmed: 29543797
Bull World Health Organ. 1979;57(4):655-62
pubmed: 316743

Auteurs

Housseini Dolo (H)

Filariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, Point G, Bamako, Mali.
Global Health Institute, Faculty of Medicine & Health Sciences, University of Antwerp, Antwerp, Belgium.

Yaya Ibrahim Coulibaly (YI)

Filariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, Point G, Bamako, Mali.
Centre National d'Appui à la Lutte contre la Maladie, Bamako, Mali.

Benoit Dembele (B)

Neglected Tropical Diseases Control Programme, Helen Keller Iinternational Bamako, Mali.

Boubacar Guindo (B)

Neglected Tropical Diseases Control Programme, Helen Keller Iinternational Bamako, Mali.

Siaka Yamoussa Coulibaly (SY)

Filariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, Point G, Bamako, Mali.

Ilo Dicko (I)

Filariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, Point G, Bamako, Mali.

Salif Seriba Doumbia (SS)

Filariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, Point G, Bamako, Mali.

Massitan Dembele (M)

Programme National d'Elimination de la Filariose Lymphatique, Bamako, Mali.

Mamadou Oumar Traore (MO)

Programme National de Lutte contre l'Onchocercose, Bamako, Mali.

Seydou Goita (S)

Neglected Tropical Diseases Control Programme, Helen Keller Iinternational Bamako, Mali.

Mamadou Dolo (M)

Institut National de Recherche en Santé Publique, Bamako, Mali.

Lamine Soumaoro (L)

Filariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, Point G, Bamako, Mali.

Michel Emmanuel Coulibaly (ME)

Filariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, Point G, Bamako, Mali.

Abdallah Amadou Diallo (AA)

Filariasis Unit, International Center of Excellence in Research, Faculty of Medicine and Odontostomatology, Point G, Bamako, Mali.

Dansine Diarra (D)

Faculty of Geography and History, Bamako, Mali.

Yaobi Zhang (Y)

Helen Keller International, Regional Office for Africa, Dakar, Senegal.

Robert Colebunders (R)

Global Health Institute, Faculty of Medicine & Health Sciences, University of Antwerp, Antwerp, Belgium.

Thomas B Nutman (TB)

Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH